These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 9726092)

  • 1. Irinotecan in the first-line treatment of colorectal cancer.
    Saltz LB
    Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):54-8. PubMed ID: 9726092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of irinotecan in colorectal cancer.
    Saltz LB
    Curr Oncol Rep; 1999; 1(2):155-60. PubMed ID: 11122813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on European adjuvant trials with irinotecan for colorectal cancer.
    Douillard JY; Barbarot V; Bennouna J
    Oncology (Williston Park); 2002 Apr; 16(4 Suppl 3):13-5. PubMed ID: 12014862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current status of colorectal cancer: CPT-11 (irinotecan), a therapeutic innovation.
    Cunningham D
    Eur J Cancer; 1996; 32A Suppl 3():S1-8. PubMed ID: 8943658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Second-line irinotecan chemotherapy in the treatment of metastatic colorectal cancers: phase III trials].
    Mitry E; Ducreux M; Rougier P
    Bull Cancer; 1998 Dec; Spec No():38-42. PubMed ID: 9932083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Irinotecan: toward clinical end points in drug development.
    Pazdur R
    Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):13-21. PubMed ID: 9726086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. US pivotal studies of irinotecan in colorectal carcinoma.
    Pitot HC
    Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):48-53. PubMed ID: 9726091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New agents in gastrointestinal malignancies: Part 1: Irinotecan in clinical practice.
    Stucky-Marshall L
    Cancer Nurs; 1999 Jun; 22(3):212-9. PubMed ID: 10376382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Irinotecan as first-line treatment of colorectal cancer: new indication. A modest advantage.
    Prescrire Int; 2001 Apr; 10(52):41-3. PubMed ID: 11718156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Irinotecan/thalidomide in metastatic colorectal cancer.
    Govindarajan R
    Oncology (Williston Park); 2002 Apr; 16(4 Suppl 3):23-6. PubMed ID: 12014864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Irinotecan monotherapy in the treatment of colorectal cancers: results of phase II trials].
    Van Cutsem E; Peeters M
    Bull Cancer; 1998 Dec; Spec No():33-7. PubMed ID: 9932082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CPT-11: an original spectrum of clinical activity.
    Rothenberg ML
    Semin Oncol; 1996 Feb; 23(1 Suppl 3):21-6. PubMed ID: 8633249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Irinotecan versus infusional 5-fluorouracil: a phase III study in metastatic colorectal cancer following failure on first-line 5-fluorouracil. V302 Study Group.
    Van Cutsem E; Blijham GH
    Semin Oncol; 1999 Feb; 26(1 Suppl 5):13-20. PubMed ID: 10213010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Irinotecan for metastatic colorectal cancer.
    Med Lett Drugs Ther; 1997 Jan; 39(992):8. PubMed ID: 9008684
    [No Abstract]   [Full Text] [Related]  

  • 15. CPT-11 (irinotecan) in the treatment of colorectal cancer.
    Armand JP; Ducreux M; Mahjoubi M; Abigerges D; Bugat R; Chabot G; Herait P; de Forni M; Rougier P
    Eur J Cancer; 1995; 31A(7-8):1283-7. PubMed ID: 7577037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of advanced or recurrent colorectal cancer with irinotecan in Japan and elsewhere.
    Sato T; Hatate K; Ikeda A; Yamanashi T; Ozawa H; Onosato W; Nakamura T; Ihara A; Watanabe M
    Expert Opin Pharmacother; 2008 May; 9(7):1223-8. PubMed ID: 18422478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Irinotecan. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer.
    Wiseman LR; Markham A
    Drugs; 1996 Oct; 52(4):606-23. PubMed ID: 8891470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase III study of irinotecan (CPT-11) versus best supportive care in patients with metastatic colorectal cancer who have failed 5-fluorouracil therapy. V301 Study Group.
    Cunningham D; Glimelius B
    Semin Oncol; 1999 Feb; 26(1 Suppl 5):6-12. PubMed ID: 10213009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDA approves irinotecan as first-line therapy for colorectal cancer.
    Oncology (Williston Park); 2000 May; 14(5):652, 654. PubMed ID: 10853457
    [No Abstract]   [Full Text] [Related]  

  • 20. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer.
    Cunningham D; Pyrhönen S; James RD; Punt CJ; Hickish TF; Heikkila R; Johannesen TB; Starkhammar H; Topham CA; Awad L; Jacques C; Herait P
    Lancet; 1998 Oct; 352(9138):1413-8. PubMed ID: 9807987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.